There are currently seven FDA-approved BsAbs for cancer treatment, four of which are BiTEs: blinatumomab targeting CD3 and CD19 for acute lymphoblastic leukemia, tebentafusp-tebn targeting CD3 and gp100 for uveal melanoma, mosunetuzumab-axgb targeting CD3 and CD20 for follicular lymphoma, epcoritamab-bysp and glofitamab-gxbm targeting CD3 and CD20 for B-cell lymphomas, teclistamab-cqyv targeting CD3 and BCMA for multiple myeloma, and amivantamab-vmjw targeting EGFR and MET for EGFR exon 20 insertion mutated non-small-cell lung cancer (NSCLC). The gene discussed is CD19; the disease is plasma cell myeloma.